Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 18/20 | 0.60 |
| ▸ | CDK2 | P24941 | 18/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 16/20 | 0.60 |
| ▸ | CDK6 | Q00534 | 12/20 | 0.60 |
| ▸ | CDK4 | P11802 | 9/20 | 0.60 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.60 |
| ▸ | CDK9 | P50750 | 3/20 | 0.60 |
| ▸ | CCND2 | P30279 | 6/20 | 0.55 |
| ▸ | CCND3 | P30281 | 6/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.49 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19857389 | 1.00 | CCND1 (0.60) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL29798894 | 0.87 | CCNE1 (0.65) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL19863588 | 0.87 | CCNE1 (0.65) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL29507679 | 0.86 | CDK2 (0.48) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL22860376 | 0.84 | CCNE1 (0.44) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL26758841 | 0.84 | CCNE1 (0.61) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL26098023 | 0.81 | CCNE1 (0.50) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL30312005 | 0.81 | CCNE1 (0.50) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL24572618 | 0.80 | CCNE1 (0.64) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL29640946 | 0.80 | CCNE1 (0.64) | CCND1CDK2CCNE1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573094-A2 | CDK2 INHIBITORS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-115702155-B | Novel pyrido [2,3-d ] pyrimidin-7 (8H) -one derivatives | 微境生物医药科技(上海)有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20250018049-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-114394966-B | Pyridopyrimidinone CDK2/4/6 inhibitors | 辉瑞公司 | 2024-10-11 | — | — | CN | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024039903-A2 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4267575-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116390921-A | Heterocyclic compound with cyclin-dependent kinase inhibition activity, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115702155-A | Novel pyrido [2,3-d ] pyrimidin-7 (8H) -one derivatives | 微境生物医药科技(上海)有限公司 | 2023-02-14 | — | — | CN | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018049-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | CDK2, SKP2, CDK5 | CCND1 125/4885CDK2 1/4885CCNE1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.